Micromet to Host Annual Research & Development Day on February 10, 2010

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM – 11:00 AM ET at the Yale Club in New York City.  Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE® antibodies.

Interested parties may access a live audio webcast of the presentation via the homepage of the Micromet website, www.micromet-inc.com or by dialing 866-700-7477 (U.S.) or 617-213-8840 (International), passcode: 23649136.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.

SOURCE Micromet, Inc.